SCHEMBL3113789

SCHEMBL3113789

O=Cc1ccc([N+](=O)[O-])c(Cl)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.73
TSHR P16473 1/20 0.60
MAPK1 P28482 1/20 0.60
ALDH5A1 P51649 1/20 0.58
ABAT P80404 1/20 0.58
ALDH1A1 P00352 3/20 0.55
KDM4A O75164 1/20 0.50
KDM4B O94953 1/20 0.50
ALDH3A1 P30838 2/20 0.49
ALDH1A3 P47895 2/20 0.49
MAPT P10636 2/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PDE7A Q13946 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16958859 0.85 TSHR (0.60) VCAM1TSHRMAPK1ALDH5A1ABAT
SCHEMBL560001 0.85 VCAM1 (1.00) VCAM1MAPK1ALDH5A1ABATALDH1A1
SCHEMBL14564665 0.83 TSHR (0.58) VCAM1TSHRMAPK1ALDH5A1ABAT
SCHEMBL16954832 0.83 MAPK1 (0.58) VCAM1TSHRMAPK1ALDH5A1ABAT
SCHEMBL31484716 0.82 ALDH5A1 (0.69) VCAM1TSHRALDH5A1ABATALDH1A1
SCHEMBL1466944 0.82 ALDH5A1 (0.69) VCAM1TSHRALDH5A1ABATALDH1A1
SCHEMBL28519167 0.80 FBP1 (0.58) VCAM1TSHRMAPK1KDM4AKDM4B
SCHEMBL28519165 0.80 FBP1 (0.58) VCAM1TSHRMAPK1KDM4AKDM4B
SCHEMBL12492068 0.79 MAPK1 (0.53) VCAM1TSHRMAPK1ALDH1A1KDM4A
SCHEMBL12492067 0.79 MAPK1 (0.53) VCAM1TSHRMAPK1ALDH1A1KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 EP disclosed
WO-2024255765-A1 NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-12-19 WO disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
CN-117355521-A Heteroaryl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 CN disclosed
CN-116903469-A Synthesis method of 4-nitrobenzophenone compound 台州学院 2023-10-20 CN disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed
US-9371319-B2 Pyrrolopyridineamino derivatives as MPS1 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-21 US disclosed
EP-2686318-B1 PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS CANCER REC TECH LTD (GB) 2016-03-09 EP disclosed
WO-2009002916-A2 PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORPORATION (US) 2008-12-31 WO disclosed
US-20070027143-A1 Novel substituted 2,3-benzodiazepine derivatives IVAX DRUG RESEARCH INSTITUTE, LTD. (HU) 2007-02-01 US disclosed
CN-1747938-A Novel substituted 2, 3-benzodiazepine * derivatives IVAX INST FOR DRUG RES LTD (HU) 2006-03-15 CN disclosed
US-4962146-A 3-O-glycosyl 16-membered macrolide antibacterials and related derivatives SCHERING CORPORATION (US) 1990-10-09 US disclosed
US-4945021-A ELECTROGRAPHY; DISPERSIBILITY, POT LIFE; PHOTOSENSITIVITY DURABILITY MINOLTA CAMERA KABUSHIKI KAISHA (JP) 1990-07-31 US disclosed
EP-0362267-A1 3-O-GLYCOSYL 16-MEMBERED MACROLIDE ANTIBACTERIALS AND RELATED DERIVATIVES SCHERING CORPORATION (US) 1990-04-11 EP disclosed
US-4808575-A BACTERICIDES, ANTIBIOTIC SCHERING CORPORATION (US) 1989-02-28 US disclosed
EP-0290203-A1 3-O-glycosyl 16-membered macrolide antibacterials and related derivatives SCHERING CORPORATION (US) 1988-11-09 EP disclosed
WO-1988008426-A1 3-O-GLYCOSYL 16-MEMBERED MACROLIDE ANTIBACTERIALS AND RELATED DERIVATIVES SCHERING CORPORATION (US) 1988-11-03 WO disclosed
US-4205193-A CATALYST FROM ALUMINUM AND TITANIUM COMPOUND, ORGANOOXYGEN COMPOUND AND ORGANOSULFUR CONTAINING COMPOUND MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) 1980-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 VCAM1 577/4885TSHR 4000/4885MAPK1 3772/4885
US-20070027143-A1 Novel substituted 2,3-benzodiazepine derivatives GABRB2, GABRB3, GABRA2 VCAM1 1711/4885TSHR 2291/4885MAPK1 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.